UH has found a way to instantly zap COVID-10. Andriy Onufriyenko/Getty Images

While the world rushes to find a COVID-19 vaccine, scientists from the University of Houston have found a way to trap and kill the virus — instantly.

The team has designed a "catch and kill" air filter that can nullify the virus responsible for COVID-19. Researchers reported that tests at the Galveston National Laboratory found 99.8 percent of the novel SARS-CoV-2 — which causes COVID-19 — was killed in a single pass through the filter.

Zhifeng Ren, director of the Texas Center for Superconductivity at UH, collaborated with Monzer Hourani, CEO of Medistar, a Houston-based medical real estate development firm, plus other researchers to design the filter, which is described in a paper published in Materials Today Physics.

Researchers were aware the virus can remain in the air for about three hours, which required a filter that could quickly remove it. The added pressure of businesses reopening created an urgency in controlling the spread of the virus in air conditioned spaces, according to UH.

Meanwhile, to scorch the virus — which can't survive above around 158 degrees Fahrenheit — researchers instilled a heated filter. By blasting the temperature to around 392 F, they were able to kill the virus almost instantly.

The filter also killed 99.9 percent of the anthrax spores, according to researchers.

A prototype was built by a local workshop and first tested at Ren's lab for the relationship between voltage/current and temperature; it then went to the Galveston lab to be tested for its ability to kill the virus. Ren says it satisfies the requirements for conventional heating, ventilation and air conditioning (HVAC) systems.

"This filter could be useful in airports and in airplanes, in office buildings, schools and cruise ships to stop the spread of COVID-19," said Ren, MD Anderson Chair Professor of Physics at UH and co-corresponding author for the paper, in a statement. "Its ability to help control the spread of the virus could be very useful for society."

Medistar executives are also proposing a desk-top model, capable of purifying the air in an office worker's immediate surroundings, Ren added.

Developers have called for a phased roll-out of the device, with a priority on "high-priority venues, where essential workers are at elevated risk of exposure — particularly schools, hospitals and health care facilities, as well as public transit environs such as airplanes."

The hope, developers add, is that the filter will protect frontline workers in essential industries and allow nonessential workers to return to public work spaces.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”